Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is a promising medical device company with a positive outlook for revenue and gross margin growth this year, as well as potential partnerships, product launches, and market expansion. While its profitability outlook has decreased, the company is expected to see future growth and profitability. However, there are potential risks and challenges that could impact the company's performance and stock value. A buy rating and price target of $18 have been given based on projected revenue growth and profitability in the upcoming years.

Bears say

SI-BONE is currently experiencing strong revenue growth, however their dependence on a single anatomical location and potential headwinds in reimbursement and coverage could impact future growth and profitability. With a relatively high valuation and increasing competition in the market, there are risks to consider when investing in SI-BONE. However, their focus on a specialized niche and differentiated products could also lead to sustained growth and above-average profitability in the future. More research and monitoring of the company's market penetration and competitive landscape may be needed to fully assess their potential.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.